TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,777,861 | -45.6% | 441,267 | -20.3% | 0.02% | -52.8% |
| Q1 2023 | $12,453,005 | +196.1% | 553,713 | +176.8% | 0.04% | +176.9% |
| Q4 2022 | $4,206,231 | +56.4% | 200,011 | +83.2% | 0.01% | +44.4% |
| Q3 2022 | $2,690,000 | -44.6% | 109,166 | -45.5% | 0.01% | -43.8% |
| Q2 2022 | $4,854,000 | -13.0% | 200,333 | -7.5% | 0.02% | 0.0% |
| Q1 2022 | $5,581,000 | +84.6% | 216,587 | +122.4% | 0.02% | +166.7% |
| Q4 2021 | $3,023,000 | +260.7% | 97,400 | +190.3% | 0.01% | +200.0% |
| Q1 2021 | $838,000 | -22.4% | 33,550 | -15.4% | 0.00% | -33.3% |
| Q4 2020 | $1,080,000 | – | 39,637 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |